| |
Colorectal cancer
|
|---|
| |
Sensitivity
|
Specificity
|
|---|
|
Two markers
|
Both positive
|
Either positive
|
Both negative
|
Either negative
|
|---|
|
PAI-1 + CATB
|
78%
|
98%
|
73%
|
98%
|
|
PAI-1 + uPA
|
64%
|
98%
|
67%
|
98%
|
|
PAI-1 + CATL
|
39%
|
96%
|
67%
|
96%
|
|
CATB + uPA
|
55%
|
95%
|
79%
|
87%
|
|
CATB + CATL
|
41%
|
84%
|
75%
|
94%
|
|
CATL + uPA
|
30%
|
80%
|
72%
|
90%
|
|
PAI-1 + CEA
|
30%
|
96%
|
73%
|
98%
|
|
CATB + CEA
|
28%
|
84%
|
83%
|
95%
|
|
uPA + CEA
|
20%
|
80%
|
76%
|
95%
|
|
CATL + CEA
|
20%
|
52%
|
75%
|
94%
|
|
PAI-1 + CA 19-9
|
18%
|
96%
|
77%
|
98%
|
|
CATB + CA 19-9
|
16%
|
84%
|
86%
|
97%
|
|
uPA + CA 19-9
|
14%
|
73%
|
80%
|
95%
|
|
CATL + CA 19-9
|
11%
|
48%
|
78%
|
95%
|
|
CEA + CA 19-9
|
16%
|
32%
|
86%
|
97%
|
|
Three markers
|
All positive
|
Either positive
|
All negative
|
Either negative
|
|
PAI-1 +CEA +CA 19-9
|
16%
|
96%
|
71%
|
98%
|
|
CATB +CEA +CA 19-9
|
14%
|
84%
|
80%
|
97%
|
|
uPA +CEA +CA 19-9
|
12%
|
80%
|
74%
|
97%
|
|
CATL +CEA +CA 19-9
|
9%
|
52%
|
74%
|
97%
|
- Sensitivity and specificity values of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 during multiparametric tumor marker analysis in colorectal cancer (n = 56)
- CATB: cathepsin B; CATL: cathepsin L; uPA: urokinase-type plasminogen activator, PAI-1: plasminogen activator inhibitor type-1; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 19-9;
- Both: both markers correctly positive or negative; All: all three markers correctly positive or negative; Either: one of two/or three markers correctly positive or negative
